Fairfax County Health Department Tuberculosis Program Annual Report - 2022

In 2022, the Fairfax Health District (FHD) reported 55 tuberculosis (TB) cases (rate: 4.6 per 100,000). For Virginia, during 2022, 195 TB cases (rate: 2.3 per 100,000) were confirmed, with FHD comprising 28.2% of the statewide total. FHD statistics are included in the Northern Health Region, which, in 2022, collectively accounted for 57.9% of the state's TB cases.

FHD's higher TB rate reflects the diversity of our population, which includes individuals from countries with high TB burdens. The pattern of slowing decline in TB morbidity during the period preceding the COVID-19 pandemic, a notable drop during the peak pandemic years, and recent partial rebound has been observed for the United States (US), Virginia, and FHD.

TB disease is a reportable condition in Virginia. Clinicians, hospitals, and laboratories are all required to report TB cases (laboratory-confirmed and clinical) and presumptive cases to the local Health Department. To report TB cases, suspect TB cases, or patients who are started on four-drug TB therapy, please contact the Fairfax County Health Department (FCHD) at (703) 246-2433. The Health Department offers evaluation and treatment of active TB disease and latent TB infection (LTBI).

CHARACTERISTIC	2	2021		2022	
	Number	Percent	Number	Percent ^a (% Change)	
Number of cases	50		55	10.0ª	
Case rate (per 100,000 population)	4.2 ^b		4.6 ^b	9.5ª	
	AGE				
• ≤ 14 years	0	0.0	0	0.0	
• 15 to 24 years	1	2.0	5	9.1	
• 25 to 44 years	15	30.0	10	18.2	
• 45 to 64 years	17	34.0	19	34.5	
• ≥ 65 years	17	34.0	21	38.2	
,			<u> </u>		
	SEX				
• Female	18	36.0	23	41.8	
• Male	32	64.0	32	58.2	
mare	52	01.0	52	50.2	
	RACE/ETHNI	CITY			
• American Indian/Alaska Native,					
not Hispanic/Latino	0	0.0	0	0.0	
Asian, not Hispanic/Latino	33	66.0	34	61.8	
Black, not Hispanic/Latino	7	14.0	5	9.1	
White, not Hispanic/Latino	2	4.0	0	0.0	
Multi-race, not Hispanic/Latino	2	4.0	6	10.9	
Hispanic/Latino	6	12.0	10	18.2	
	PLACE OF B	IRTH	0	-1	
• US Born	3	6.0	4	0.0	
 US-Born case rate (per 100,000 population) 	0.4 ^b		0.0 ^b		
Non-US Born	47	94.0	55	100.0	
 Non-US-Born case rate (per 100,000 population) 	13.0 ^b		15.2 ^b		
^b Source (population denominator): US Censu	us Bureau, 2017-20	21 American Comr	nunity Survey 5-y	ear Estimates	
YE	EARS OF U.S. R	ESIDENCY			
• < 1 year	3	6.7	5	9.8	
• 1 to 3 years	7	15.6	4	7.8	
• 4 to 5 years	4	8.9	5	9.8	
• > 5 years	31	68.9	37	72.5	

CHARACTERISTIC	2021		2022				
	Number	Percent	Number	Percent			
COUNTRY OF ORIGIN (for those countries with ≥ 5 cases reported in 2022)							
• India	10	20.0	10	18.2			
• Vietnam	5	10.0	9	16.4			
• China	3	6.0	5	9.1			
• Others	32 (16 countries)	64.0	31 (17 countries)	56.4			
DRUG RESISTANCE							
• INH (INH only or INH + other drugs)	4	9.8	6	13.0°			
• Multi-drug resistant (INH + Rifampin with or without resistance to other drugs)	0	0.0	0	0.0°			
^c The denominator for 2022 is 46 <i>M. tuberculo</i>	sis culture-positive	e cases with initial of	lrug susceptibility	testing done.			
HIV CO-INFECTION							
HIV Co-infection	0	0.0	0	0.0			

Mandated Reporting of Tuberculosis Infection (LTBI)

On November 14, 2018, TB infection, in persons of any age, was added to the <u>Virginia Reportable Disease List</u>. Under the updated <u>Virginia Regulations for Disease Reporting and Control</u> (12 VAC 5-90-80), healthcare providers are required to report suspected or confirmed cases of TB infection to the local health department serving the jurisdiction where they practice.

For the Fairfax Health District (FHD), the preferred reporting method is online via the Fairfax County Health Department TB webpage (<u>https://www.fairfaxcounty.gov/health/tuberculosis/providers</u>) where a direct link is provided to the Virginia Department of Health reporting portal. Through this portal, healthcare providers can complete and submit an electronic Confidential Morbidity Report (or Epi-1). TST/IGRA results should be entered in the laboratory section of the electronic report form. Document chest X-ray results and symptom screening information, as well as treatment information, in the comments section.

In 2022, FHD reported 2,683 cases of TB infection, representing 28.1% of Virginia's LTBI morbidity. Of these FHD LTBI cases, 71 (2.6%) and 2,612 (97.4%) were categorized as confirmed (TB disease ruled out) and suspect (only TST or IGRA results reported), respectively.^d

For questions regarding the TB infection reporting requirement, or guidance regarding screening and treatment for TB infection, please call the FCHD TB intake line at 703-246-2433.

^dLTBI data are preliminary and subject to change.

Clinician Notes: Key Take-Aways

- Fairfax Health District is a high-incidence area for TB. Most patients with active disease have reactivation of LTBI acquired during residence in a TB endemic country.
- Non-US-born persons, from countries with high TB incidence (see <u>High Burden TB Country List 2023</u>), are a priority group for screening regardless of length of residence in the US. Within this group, highest priority for TST or IGRA testing are persons who have underlying conditions that may affect their immune status (e.g., HIV, diabetes mellitus).
- The CDC and the National TB Controllers Association preferentially recommend short-course, rifamycin-based 3- or 4month LTBI treatment regimens over 6- or 9-month based isoniazid therapy. More information can be found in the Virginia Department of Health's LTBI Provider Toolkit: <u>TB Infection (LTBI) - Tuberculosis (virginia.gov)</u>.